Long title
Administration of genetically engineered T cells (KTE-X19) in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Date receipt dossier
EudraCT number
2015-005010-30
Company / Sponsor
Kite Pharma
Phase
I/II
Treated organism
Humans
Indication category
Cancer therapy
Disease
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Therapeutic approach
Immunotherapy
Genetic modification
CD19-CAR
Method of transfer of nucleic acid of interest
Retroviral vector
Administered biological material
Autologous T-cells retrovirally transduced with CD19-CAR
Route of administration
Intravenous
Locations in Belgium
UZ Gent
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
KTE-X19